Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Sales (2016 - 2025)

Avalo Therapeutics' Return on Sales history spans 12 years, with the latest figure at 232.54% for Q4 2025.

  • For Q4 2025, Return on Sales fell 4849.0% year-over-year to 232.54%; the TTM value through Dec 2025 reached 1326.42%, down 124677.0%, while the annual FY2025 figure was 1326.42%, 124677.0% down from the prior year.
  • Return on Sales reached 232.54% in Q4 2025 per AVTX's latest filing, up from 520.2% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 165.56% in Q1 2025 to a low of 520.2% in Q3 2025.
  • Average Return on Sales over 5 years is 52.5%, with a median of 12.74% recorded in 2023.
  • The largest YoY upside for Return on Sales was 26410bps in 2025 against a maximum downside of -61272bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.3% in 2021, then skyrocketed by 99bps to 0.0% in 2022, then crashed by -382254bps to 14.3% in 2023, then plummeted by -1187bps to 184.06% in 2024, then decreased by -26bps to 232.54% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Return on Sales are 232.54% (Q4 2025), 520.2% (Q3 2025), and 104.8% (Q2 2025).